Date: 9th June 2015
Cambridge, UK, 9th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.
The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.
The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.
ELC Group selected the products based on a number of key criteria, including global market size, annual drug sales, prior experience, expertise, and therapeutic categories. Some of the products are being developed with very specific IP considerations and will qualify as Paragraph IV filings in the US, 505 b2 applications in the US, Hybrid applications in the EU, and first generics.
Commenting on the new product portfolio development, ELC Group CEO Marco Rubinstein said: “Our rapid growth, built on intense demand from our global customers, has meant that our business has been naturally moving towards this solution expansion for some time. We have some of the world’s leading experts working on the development of these products and we are keenly anticipating bringing them successfully to market in the near future.”
- Ends -
Note to editors:
If you would be interested in scheduling a briefing with ELC Group, please contact Nicky Denovan at nicky[at]evokedset[dot]com.
ajain [at] elc-group [dot] com
Phone: +420 22 491 00 00
nicky[at] evokedset [dot] com
Phone: +44 (0)118 3282782
About ELC Group:
ELC GROUP is a fully-fledged global regulatory partner, working with major pharmaceutical stakeholders for over a decade.
From Concept to Commercialisation is one of the key partnership areas in which ELC GROUP is creating its fast-growing success. From the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product, ELC GROUP aligns itself as a strategic partner to help pharmaceutical companies achieve their healthcare goals.
ELC GROUP’s worldwide network of professionals spans all major Regulatory Affairs services across the key healthcare vertical markets of Pharmaceuticals, Biotech, Clinical, Consumer Healthcare, Medical Devices, Nutraceuticals and Veterinary. The team ranges from former FDA investigators to individuals with over 30 years of industry experience and broad capabilities, including in the areas of integrated advanced technologies, Regulatory Affairs consulting and commercialisation services.
ELC GROUP works with equal success in partnership with large multi-nationals, small enterprises and start-ups, biotechs, CROs and device manufacturers.